Study of VX-661 Alone and in Combination With Ivacaftor in Subjects Homozygous or Heterozygous to the F508del-Cystic Fibrosis Transmembrane Conductance Regulator(CFTR) Mutation
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Scott Donaldson, MD
University of North Carolina
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
36 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Vertex Investigational Site
Calgary, Alberta, Canada
- Vertex Investigational Site
Vancouver, British Columbia, Canada
- Vertex Investigational Site
Halifax, Nova Scotia, Canada
- Vertex Investigational Site
Toronto, Ontario, Canada
- Vertex Investigational Site
Erlangen, Bavaria, Germany
- Vertex Investigational Site
Frankfurt am Main, Hesse, Germany
- Vertex Investigational Site
Hanover, Lower Saxony, Germany
- Vertex Investigational Site
Cologne, North Rhine-Westphalia, Germany
- Vertex Investigational Site
Berlin, Germany
- Vertex Investigational Site
Bochum, Germany
- Vertex Investigational Site
Jena, Germany
- Vertex Investigational Site
Munich, Germany
- Vertex Investigational Site
Cambridge, Cambridgeshire, United Kingdom
- Vertex Investigational Site
London, Greater London, United Kingdom
- Vertex Investigational Site
Manchester, Greater Manchester, United Kingdom
- Vertex Investigational Site
Southhampton, Hampshire, United Kingdom
- Vertex Investigational Site
Cardiff, Vale of Glamorgen, United Kingdom
- Vertex Investigational Site
Birmingham, Alabama, United States
- Vertex Investigational Site
Oakland, California, United States
- Vertex Investigational Site
Boise, Idaho, United States
- Vertex Investigational Site
Chicago, Illinois, United States
- Vertex Investigational Site
Boston, Massachusetts, United States
- Vertex Investigational Site
Grand Rapids, Michigan, United States
- Vertex Investigational Site
Kansas City, Missouri, United States
- Vertex Investigational Site
Long Branch, New Jersey, United States
- Vertex Investigational Site
New Hyde Park, New York, United States
- Vertex Investigational Site
Chapel Hill, North Carolina, United States
- Vertex Investigational Site
Cincinnati, Ohio, United States
- Vertex Investigational Site
Columbus, Ohio, United States
- Vertex Investigational Site
Oklahoma City, Oklahoma, United States
- Vertex Investigational Site
Hershey, Pennsylvania, United States
- Vertex Investigational Site
Pittsburgh, Pennsylvania, United States
- Vertex Investigational Site
Charleston, South Carolina, United States
- Vertex Investigational Site
Salt Lake City, Utah, United States
- Vertex Investigational Site
Burlington, Vermont, United States
- Vertex Investigational Site
Seattle, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 29 Feb 2012
- Primary completion
- 31 Mar 2014
- Completion
- 31 Mar 2014
- Last update posted
- 13 Apr 2018
- Registered enrollment
- 194
- Registry id
- NCT01531673
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.